Discover
IMRX
Immuneering Corporation
5.05
2 x 3.64
2 x 6.29
bid
ask
+
0.06
1.20%
2 @ 04:00 PM
4.91 -0.14 (2.77%)
| Ytd | -23.25% | |
| 1y | 46.80% |
4.88
day range
5.17
2.90
52 week range
10.08
| Open | 5.02 | Prev Close | 4.99 | Low | 4.88 | High | 5.17 | Mkt Cap | 326.72M |
| Vol | 1.07M | Avg Vol | 1.50M | EPS | -1.06 | P/E | N/A | Forward P/E | -1.34 |
| Beta | -0.40 | Short Ratio | 1.19 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.94 | 200-d Avg | 5.71 | 1yr Est | 12.42 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.54 | -0.49 | 0.05 | 9.26% |
| 2024-08-06 | 2024-06 | -0.51 | -0.47 | 0.04 | 7.84% |
| 2024-08-06 | 2024-06 | -0.51 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.45 | -0.49 | -0.04 | -8.89% |
| 2024-05-07 | 2024-03 | -0.45 | N/A | N/A | N/A |
| 2024-03-01 | 2023-12 | -0.48 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-20 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-11-14 | Needham | Upgrade | Buy | Buy |
| 2024-09-13 | Needham | Upgrade | Buy | Buy |
| 2024-08-07 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-08-07 | Needham | Upgrade | Buy | Buy |
| 2024-05-08 | Needham | Upgrade | Buy | Buy |
Profile
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-17 | BERMAN ANN E | Director | 67.47K | Purchase |
| 2024-03-14 | BOOKMAN MICHAEL | Officer | 3.85K | Stock Award(Grant) |
| 2024-03-21 | BRAKEWOOD HAROLD EUGENE | Officer | 3.90K | Purchase |
| 2024-03-31 | CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-03-21 | FEINBERG PETER | Director | 1.10M | Purchase |
| 2024-03-19 | HALL BRETT MATTHEW | Officer | 345.90K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 1.07M | 2.35M | 3.45% |
| 2024-09-29 | Price (T.Rowe) Associates Inc | 810.13K | 1.78M | 2.61% |
| 2024-09-29 | Morgan Stanley | 449.31K | 988.48K | 1.45% |
| 2024-09-29 | Blackrock Inc. | 318.42K | 700.52K | 1.03% |
| 2024-09-29 | Millennium Management Llc | 246.27K | 541.79K | 0.79% |
| 2024-09-29 | Geode Capital Management, LLC | 209.64K | 461.21K | 0.68% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 736.19K | 1.62M | 2.37% |
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 509.13K | 1.12M | 1.64% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 289.20K | 636.23K | 0.93% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 118.33K | 260.32K | 0.38% |
| 2024-08-30 | ETF Series Solutions-Range Cancer Therapeutics ETF | 64.04K | 140.88K | 0.21% |
| 2024-10-30 | iShares Micro Cap ETF | 49.85K | 109.67K | 0.16% |